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adherence various. This original approach could be useful to
perform budget impact studies before implementing large public
health screening programs.
PCN27
COST-EFFECTIVENESS ANALYSIS OF SCREENING SUBJECTS
WITH DIFFERENT LEVELS OF RISK FOR HEPATOCELLULAR
CARCINOMA INTAIWAN
Chang Y
UT, Houston,TX, USA
OBJECTIVE: The American Association for the Study of Liver
Diseases 2005 practice guidelines recommended that various
groups at different levels of risk to hepatocellular carcinoma
(HCC) undergo surveillance. This study aimed to assess which
high risk group had the lowest incremental cost-effectiveness
ratio (ICER) for the HCC screening program from the insurer’s
perspective. METHODS: The high risk subjects were identiﬁed
from the communities with high prevalence of hepatitis viral
infection and classiﬁed into three groups at different levels of
risk to HCC at the time of enrollment. The repeated ultrasound
screenings at an interval of three, six, and twelve months were
applied to cirrhosis group, early cirrhosis group, and no cir-
rhosis group, respectively. The Markov-based decision model
was constructed to simulate progression of HCC and to esti-
mate the ICER for each group over a time horizon of 50 years
or the subjects’ remaining life expectancy. Validity of the model
outcomes was examined against the health statistics. RESULTS:
The incremental ICER for the cirrhosis group, early cirrhosis
group, and no cirrhosis group were $1375, $816, and $861,
respectively. Among the three groups, the early cirrhosis group
had the highest incremental effect (3.41 years per person) and
the cirrhosis group had the largest incremental cost ($4247 per
person). It is noteworthy that when compared to the other two
groups, the cirrhosis group showed the lowest incremental
effect (2.03 year) and the highest incremental cost ($4247).
CONCLUSION: Screening the no cirrhosis group for HCC at a
12-month interval had the lowest incremental cost-effectiveness
ratio.
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OBJECTIVE: This study is intended to evaluate the costs derived
from the treatment of aggressive and indolent Non-Hodgkin
Lymphoma (NHL), in patients treated with R-CHOP vs. CHOP
in order to provide solid pharmacoeconomic arguments for
decision-makers in regards to a cost-effective therapy for patients
with NHL and hence have a more efﬁcient allocation of
resources. METHODS: A cost-effectiveness analysis model was
developed based on the efﬁcacy reports of the international lit-
erature in regards to treatment of NHL estimating the probabili-
ties of no remission or disease relapse and the costs of treatment
failure and those derived from salvage therapies used. This was
calculated in a time horizon of 3 years with a 5% discount rate,
based on public health care institutions perspective. RESULTS:
The results of the model using a cohort of 200 hypothetic NHL
patients, 100: aggressive-NHL and 100: indolent-NHL, in which
50% received treatment with R-CHOP and the other half
with CHOP showed that the use of Rituximab in addition to
the CHOP therapy in the case of patients with Aggressive
NHL represents savings per patient in compete remission of
USD$138,530.33. In the case of patients with Indolent NHL the
savings were USD$1,366,417.78. Both savings represents the
possibility to obtain 10 more patients in complete remission (3
and 7 respectively). CONCLUSION: The use of Rituximab in
addition to CHOP as ﬁrst line therapy for NHL is not only a
cost-effective intervention when compared to CHOP therapy
in the Mexican context, but, according to the results, it is
also a cost-saving intervention with an average saving of
USD$821,739.23.
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OBJECTIVE: The paper calculates regional generalized cost-
effectiveness estimates of screening, prevention, treatment and
combined interventions for cervical cancer. METHODS: Stan-
dardised WHO-CHOICE methodology was used. A cervical
cancer model was employed to provide estimates of screening,
vaccination and treatment effectiveness. Intervention effective-
ness was determined via a population state-transition model
(PopMod) that simulates the evolution of a sub-regional popu-
lation accounting for births, deaths and disease epidemiology.
Economic costs of procedures and treatment were estimated,
including programme overhead and training costs. RESULTS: In
regions characterised by high income, low mortality and high
existing treatment coverage, the addition of any screening pro-
gramme to the current high treatment levels is very cost effective.
However, based on projections of the future price per dose
(representing the economic costs of the vaccination excluding
monopolistic rents and vaccine development cost) vaccination is
the most cost-effective intervention. In regions characterized by
low income, low mortality and existing treatment coverage
around 50%, expanding treatment with or without combining it
with screening appears to be cost effective or very cost-effective.
Abandoning treatment in favour of screening in a no-treatment
scenario would not be cost effective. Vaccination is usually the
most cost-effective intervention, however in some regions one-off
PAP or VIA screening at age 40 are more cost-effective than other
interventions though less effective overall. In regions character-
ised by low income, high mortality and low treatment levels,
expanding treatment with or without adding screening would be
very cost-effective. One-off PAP or VIA screening at age 40 are
more cost-effective than other interventions though less effective
overall. CONCLUSION: From a cost-effectiveness perspective,
consideration should be given to implementing vaccination
(depending on cost per dose) and screening programmes on a
worldwide basis to reduce the burden of disease from cervical
cancer. Treatment should also be increased where coverage is
low.
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OBJECTIVE: Treatment options for the relatively small group
of patients resistant or intolerant to imatinib, a recommended
ﬁrst-line therapy for chronic myeloid leukemia (CML), include
nilotinib or dasatinib. Current data indicates that nilotinib and
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dasatinib have different side effect proﬁles. The aim of this
study was to investigate costs of adverse events (AEs) in
patients receiving recommended doses of nilotinib or dasatinib
for treatment of chronic and accelerated CML. METHODS:
Incidence rates of grade 3/4 AEs in CML patients treated with
nilotinib or dasatinib were obtained from clinical trial data.
Direct medical costs for non-hematological AEs and for grade 4
anemia and thrombocytopenia, and febrile neutropenia were
obtained from Ontario Case Costing Initiative (OCCI) inpatient
databases and were speciﬁc to oncology patients. Costs for
grade 3 anemia, thrombocytopenia, and non-febrile neutrope-
nia were assumed to be outpatient costs and were based on
literature and expert validation of treatment pathway and
resource utilization in the Canadian context. Multivariate sen-
sitivity analyses were conducted on costs of AEs and for an
alternative dasatinib dosing (100 mg). RESULTS: Cost of
treatment-related AEs for CML patients was highest for dasa-
tinib. Total costs for AEs associated with the accelerated phase
were higher than those associated with the chronic phase:
$19,902 versus $7,653 for dasatinib and $8,645 versus $3,790
for nilotinib, respectively. Ranking observed among treatments
for base case costs of AEs was maintained for both high and
low cost estimates, and for 100 mg dasatinib dosing, indicating
that the model was robust to variation in these parameters.
CONCLUSION: For patients resistant or intolerant to ima-
tinib, costs of dasatinib-related AEs were approximately twice
the costs of nilotinib-related AEs in both chronic and acceler-
ated phases, highlighting the importance of considering the cost
of AEs in economic evaluation of tyrosine kinase inhibitors.
Further research is needed to evaluate the impact of AEs on
health care expenditures.
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OBJECTIVES: We developed a probabilistic decision model of
cost-effectiveness for lung cancer (LC) screening with helical
computed tomography (hCT) compared with chest x-ray (CXR)
and no screening (NS) given uncertain efﬁcacy and risks of
screening in practice. METHODS: Markov model comparing NS
to CXR and hCT screening in 60-year old current smokers
screened annually until age 75 as base case using published
literature, Surveillance Epidemiology and End Results database,
and Mayo Clinic data. In the base case, we assumed stage shifts
observed with screening translate into survival beneﬁts. Sensitiv-
ity analyses evaluated cohort ages for starting and stopping
screening, screening compliance, smoking status, positive nodule
management and treatment costs. An expected value of perfect
information analysis (EVPI) was estimated to determine the value
of further research to reduce current uncertainty. RESULTS: In
the base case, CXR cost $51,245/QALY vs. NS and hCT was
dominated by CXR. The probability that CXR is cost-effective
was 94.3% at a maximum acceptable ratio of $100,000/QALY
(4.8% and 0.9% for NS and hCT, respectively). EVPI analysis
suggested that at a maximum ICER of $100,000/QALY, further
research would potentially be worth $55 million for the US
population over ten years. When it was assumed that hCT
screening did not result in any false positives necessitating
invasive surgery, hCT cost $119,571/QALY vs. CXR. CXR cost
$137,652 vs. NS for former smokers and was dominated by NS
for never smokers; hCT was dominated in both these analyses.
Results were sensitive to age at annual screening initiation and
termination. CONCLUSIONS: Assuming stage shifts observed
with LC screening translate into survival beneﬁts, hCT was, as
expected, most efﬁcacious, but also had the highest false positive
rate. The associated detrimental cost and quality of life effects
resulted in hCT being dominated by CXR (less efﬁcacious but
more speciﬁc).
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OBJECTIVE: To examine the cost-effectiveness of introducing an
HPV-16/18 prophylactic cervical cancer (CC) vaccine in a setting
of existing screening in Portugal. METHODS: A Markov cohort
simulation model was used with an annual cycle length and
which mimics the natural history of HPV infection to CC. The
analysis was undertaken from the health care system perspective.
Direct medical costs were estimated and discounted at a rate of
3%. Effect measures were: CC cases and deaths avoided, life
years saved and QALYs, discounted at a rate of 3%. The incre-
mental cost-effectiveness was estimated by comparison of the
options to be implemented with the current strategy. The analytic
horizon was lifetime where subjects enter the model at 10 years
old and are followed for 95 cycles until death. One-way sensi-
tivity analysis was conducted on the key variables. RESULTS:
Our results predicted that an HPV-16/18 vaccine targeting
12-year-old girls would be cost-effective and could reduce life-
time CC cases and mortality by 92% compared with current
screening. Vaccination was predicted to substantially reduce the
number of oncogenic HPV infections and Cervical Intraepithelial
Neoplasia cases (CIN1-3 cases). The additional cost of generat-
ing one QALY by implementing a vaccination strategy, where all
12-year-old girls are vaccinated with a vaccine showing 96.7%
efﬁcacy against HPV-16/18, was €13,810. The results were sen-
sitive to alternative assumptions about the discount rate and age
at which vaccination begins. The base-case strategy was robust to
modiﬁcations in vaccination coverage and fairly robust
to changes in both percentages of oncogenic HPV and of oppor-
tunistic screening rates. CONCLUSION: The analysis suggested
that prophylactic cervical cancer vaccination could have a sub-
stantial public health beneﬁt. A vaccine directed speciﬁcally at
reducing the incidence of oncogenic HPV types 16 and 18, during
the peak ages of infection, could be expected to be economically
attractive.
PCN33
COST UTILITY ANALYSIS OFVACCINATION AGAINST
HPV IN ISRAEL
Ginsberg GM1, Fisher M2, Ben-Shahar I3, Bornstein J4
1Ministry of Health, Jerusalem, Israel, 2Clalit Health Services, Nahariah,
Israel, 3Hadassah Hospital, Jerusalem, Israel, 4Western Galilee Hospital,
Nahariah, Israel
OBJECTIVE: Determine appropriate scenarios for screening
compliance for vervical cancer in Israel. METHODS: Genera-
lised cost-effectiveness estimates of screening (PAP, HPV-DNA,
VIA at various frequencies) and/or HPV vaccination interven-
tions for cervical cancer in Israel were calculated using WHO-
CHOICE standardised methodology, utilising a state transition
population model (POPMOD) simulating Israeli population
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